Cronos Group Inc vs iShares MBS ETF — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while iShares MBS ETF trades at $89.61 (market cap $35.41B). The key difference: iShares MBS ETF is far larger — about 30× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and iShares MBS ETF for 96 Days on average.
| CRON | MBB | |
|---|---|---|
Market Cap | $1.18B | $35.41B |
Volume | 968,037 | 5,388,525 |
Sector | Health | Fixed Income |
52-Week High | $3.55 | $96.91 |
52-Week Low | $2.30 | $89.09 |
Typical Hold Time | 22 Days | 96 Days |
Enterprise Value | $387.62M | — |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% today amid a bearish technical signal. Recent quarterly earnings show beats in Q1 and Q2 2026, with revenue growth from $118M in 2024 to $147M in 2025. The company reported a net loss of $9.45M in 2025 but projects a profit of $70M for 2026. Analyst sentiment is mixed with a 20% buy rating. News highlights focus on international expansion and a recent Investor Day outlining growth strategies.
Outlook is cautiously optimistic given projected profitability in 2026 and strong cash reserves, but risks include sustained negative cash flow and competitive pressures. The stock's valuation metrics like P/E of 16.95 and P/S of 6.84 suggest moderate pricing relative to peers, though high EV/EBITDA of 43 indicates premium expectations.
MBB, the iShares MBS ETF, trades at $89.54, up 0.36% on the day but showing a bearish technical signal overall. The ETF has faced significant short interest growth of 98.3% in September 2026, reaching 6.57 million shares, and recently hit a 52-week low. Recent news highlights concerns over intermediate duration risk amid potential rate hikes, though institutional buying from firms like Corient Private Wealth and Baird Financial Group provides some support. Key technical indicators show oversold conditions on the 12-day RSI but strong selling pressure from moving averages.
The outlook for MBB remains cautious due to interest rate sensitivity and convexity risks in the mortgage-backed securities market. While dividend payments offer income, rising rates and inflation pressures pose downside risks. Analyst sentiment is neutral to bearish, with the ETF's performance heavily tied to Federal Reserve policy. Investors should weigh the high yield against duration risk in a tightening cycle.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →